An Afro-Caribbean man was diagnosed with schizophrenia and subsequently developed cognitive and cerebellar dysfunction. Ten years later, he was genetically diagnosed with spinocerebellar ataxia type 2 (SCA2). Patients with a number of neurodegenerative disorders may develop psychotic symptoms at some point in their disease course; however, no cases have been reported in which psychosis was the presenting feature of SCA2. In SCA2, both cerebellar and basal ganglia pathologies may contribute to psychiatric disease. It remains unknown in our patient whether the psychosis should be attributed to schizophrenia or SCA2, but this case highlights the need for awareness of neurodegenerative disorders in patients with psychiatric symptoms, in particular in patients who are treated with neuroleptics and exhibit neurological abnormalities such as movement disorders.
While psychiatric and neurological illness may co-occur in one subject, a number of neurodegenerative disorders can present with a combination of psychiatric, cognitive, and neurological symptoms. Disorders affecting primarily the basal ganglia, such as Huntington’s disease, are well recognized as presenting with psychiatric symptoms, including depression and psychosis. Additionally, a variety of neuropsychiatric deficits have been reported with the spinocerebellar ataxias. We report the case of a subject with clinically diagnosed schizophrenia who subsequently developed a cerebellar syndrome that was genetically confirmed to be SCA2. While the co-occurrence of both psychiatric and neurodegenerative conditions in this subject may be coincidental, this case illustrates that the development of neurological findings in patients with psychiatric illness may indicate an underlying neurodegenerative process. If psychiatric symptoms manifest themselves before neurological symptoms, they may be attributed to an axis I diagnosis. Motor symptoms in the context of psychiatric illness may be attributed erroneously to neuroleptic side effects, which would delay neurological workup. These considerations have important implications for management and genetic counseling.
Case Presentation
Laboratory and Radiological Findings
Discussion
SCA2 is an autosomal dominant neurodegenerative disease caused by a pathological expansion of a CAG repeat sequence on chromosome 12q24 (MIM 183090). It is believed that the resultant mutated ataxin2 protein gains a toxic function leading to neuronal cell death and neurodegeneration (2), primarily in the cerebellum, brainstem, and spinal cord but also affecting the basal ganglia and cerebral cortex (3) . Typically, SCA2 develops in adulthood with slowed saccadic eye movements, peripheral neuropathy, decreased tendon reflexes, parkinsonism, myoclonus, and dementia. While most of the 28 types of autosomal dominant SCA reported to date involve some degree of neuropsychological deficit (4 – 6), including depression and personality change (7), psychosis appears to be less common. There is some evidence that SCA17 may appear with psychosis with or without chorea (8) ; however, to our knowledge, there are no cases of SCA2 in which psychosis was either the presenting symptom or a development during the course of the disease. A possible association exists between trinucleotide repeat expansions of the gene believed to cause SCA8 and susceptibility to major psychosis (9, 10) ; however, no such association has been reported for the repeat expansion that causes SCA2. In this case, we must ask whether SCA2 can account for the full spectrum of psychiatric, cognitive, and neurological symptoms or whether the concomitant diagnosis of schizophrenia is warranted.
Neurodegenerative disorders primarily affecting the striatum, such as Huntington’s disease and chorea-acanthocytosis, may present initially as movement disorders and/or psychiatric disturbances (11, 12) . When psychiatric symptoms develop in cerebellar disorders, they are often associated with neurological symptoms suggestive of striatal involvement (13) . This association suggests the possibility that psychosis in cerebellar disorders may be due to striatal involvement rather than to cerebellar pathology.
Alternatively, cerebellar dysfunction may account for psychiatric disease. In addition to the disorders of motor coordination and eye movements classically associated with cerebellar dysfunction, cerebellar abnormalities have been implicated in psychiatric disorders, including psychosis (14, 15) . It may be hypothesized that the co-occurrence of motor and psychiatric impairment in this case reflects the relative involvement of motor and cognitive domains that are known to be mediated by the frontal lobes and subserved by parallel circuits synaptically linking the frontal cortex, striatum, and thalamus (16) . Each of these frontostriatal circuits receives modulatory input from the cerebellum (17) . Within the cerebellum, the various functional domains, e.g., motor, vestibular, limbic, and cognitive, are topographically segregated (15) and form parallel interfaces with the frontostriatal circuits (17) . The diffuse atrophy of the cerebellum that our patient exhibited could conceivably contribute to dysfunction across multiple domains.
The etiology of our patient’s dementia is unclear because his neuropsychological deficits are consistent both with the type of subcortical dementia seen in a subset of schizophrenic patients (18) and with that seen in SCA2 (19, 20) . Although the precise chronology of the patient’s cerebellar disease is difficult to determine, the apparent temporal co-occurrence of the marked cognitive decline with the appearance of the first cerebellar motor impairments suggests that SCA2 accounts for the dementia.
Arguing against the hypothesis that SCA2 is responsible for our patient’s psychiatric disease is the fact that his age at presentation was typical for schizophrenia. In contrast, in SCA2, a repeat size in the range of that of our patient is typically associated with a slightly older age of onset, i.e., mid-20s to mid-50s (21) . Moreover, the development of somatic delusions, paranoia, and auditory hallucinations that resulted in the diagnosis of schizophrenia in our patient predated the appearance of chorea and other neurological symptoms by 6 years. In retrospect, however, one must question whether the physical complaints present from age 21 and interpreted as somatic delusions were in fact psychotic elaboration of sensations due to the emergence of a neurodegenerative disorder.
It is not possible to determine the etiology of our patient’s psychiatric disease or its relationship, if any, to his molecular diagnosis of SCA2. However, this case illustrates the importance of considering the possibility of neurodegenerative disease in patients who present with psychiatric symptoms. In particular, clinicians should be quick to evaluate unexpected cognitive or neurological symptoms that may be interpreted mistakenly as psychiatric in origin or as side effects of neuroleptics and anticholinergic medications. Correct and prompt diagnosis is essential for appropriate management, assessment of prognosis, and genetic counseling.
Footnotes
Received Feb. 25, 2008; revision received April 27, 2008; accepted April 28, 2008 (doi: 10.1176/appi.ajp.2008.08020285). From the Department of Neurology and the Department of Psychiatry, James J. Peters Veterans Affairs Medical Center; the Department of Neurology and the Department of Psychiatry, Mount Sinai School of Medicine, New York; and the Department of Psychiatry and Program in Cellular and Molecular Medicine, Johns Hopkins University School of Medicine, Baltimore. Address correspondence and reprint requests to Dr. Walker, Department of Neurology (127), James J. Peters Veterans Affairs Medical Center, 130 West Kingsbridge Rd., Bronx, NY 10468; [email protected] (e-mail).
Dr. Margolis is a consultant for AstraZeneca and receives research support from Amaron and Forest. Dr. Sano is a consultant/advisor for Aventis, Bayer, Forest, GlaxoSmithKline, Janssen, Martek, Medivation, Novartis, Pfizer, Bristol-Myers Squibb, Ortho McNeil, Takeda, Voyager, Esai, and Elan. The remaining authors report no competing interests.
References
1.
Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 534–537
Leroi I, O’Hearn E, Marsh L, Lyketsos CG, Rosenblatt A, Ross CA, Brandt J, Margolis RL: Psychopathology in patients with degenerative cerebellar diseases: a comparison to Huntington’s disease. Am J Psychiatry 2002; 159:1306–1314
Schneider SA, van de Warrenburg BP, Hughes TD, Davis M, Sweeney M, Wood N, Quinn NP, Bhatia KP: Phenotypic homogeneity of the Huntington diseases-like presentation in a SCA17 family. Neurology 2006; 67:1701–1703
Ikeda Y, Dalton JC, Moseley ML, Gardner KL, Bird TD, Ashizawa T, Seltzer WK, Pandolfo M, Milunsky A, Potter NT, Shoji M, Vincent JB, Day JW, Ranum LP: Spinocerebellar ataxia type 8: molecular genetic comparisons and haplotype analysis of 37 families with ataxia. Am J Hum Genet 2004; 75:3–16
Vincent JB, Yuan QP, Schalling M, Adolfsson R, Azevedo MH, Macedo A, Bauer A, DallaTorre C, Medeiros HM, Pato MT, Pato CN, Bowen T, Guy CA, Owen MJ, O’Donovan MC, Paterson AD, Petronis A, Kennedy JL: Long repeat tracts at SCA8 in major psychosis. Am J Med Genet 2000; 96:873–876
Liszewski CM, O’Hearn E, Leroi I, Gourley L, Ross CA, Margolis RL: Cognitive impairment and psychiatric symptoms in 133 patients with diseases associated with cerebellar degeneration. J Neuropsychiatry Clin Neurosci 2004; 16:109–112
Schmahmann JD: Disorders of the cerebellum: ataxia, dysmetria of thought, and the cerebellar cognitive affective syndrome. J Neuropsychiatry Clin Neurosci 2004; 16:367–378
Grafman J, Litvan I, Massaquoi S, Stewart M, Sirigu A, Hallett M: Cognitive planning deficit in patients with cerebellar atrophy. Neurology 1992; 42:1493–1496
van de Warrenburg BP, Hendriks H, Dürr A, van Zuijlen MC, Stevanin G, Camuzat A, Sinke RJ, Brice A, Kremer BP: Age at onset variance analysis in spinocerebellar ataxias: a study in a Dutch-French cohort. Ann Neurol 2005; 57:505–512
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
If the address matches an existing account you will receive an email with instructions to retrieve your username
Create a new account
Change Password
Password Changed Successfully
Your password has been changed
Login
Reset password
Can't sign in? Forgot your password?
Enter your email address below and we will send you the reset instructions
If the address matches an existing account you will receive an email with instructions to reset your password.
Change Password
Congrats!
Your Phone has been verified
×
As described within the American Psychiatric Association (APA)'s Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences. Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.